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Following nerve tissue damage, various events, such as inflammatory responses, microglial activation, endoplasmic reticulum 
stress, and apoptosis, can occur, which all lead to cell death, prevent axonal growth, and cause axonal circumvolution. So far, 
several researchers have tended to adopt strategies to reduce the harmful conditions associated with neurological disorders, 
and stem‑cell‑based therapy is one of those promising strategies. Epidermal neural crest stem cells (EPI‑NCSCs) are a  type of 
stem cell that has widely been employed for the treatment of various neurological disorders. It has been suggested that these 
stem cells perform their supportive actions primarily through the release of different neurotrophic factors. Hence, in this study, 
the neuroprotective impacts of valproic acid (VPA) and crocin were evaluated on the mRNA expression levels of brain‑derived 
neurotrophic factor (BDNF) and glial‑cell‑derived neurotrophic factor (GDNF) in EPI‑NCSCs. In this research, we isolated EPI‑NCSCs 
from the hair follicles of the rat whisker pad. Then, the cells were treated with different concentrations of VPA and crocin for 72 h. 
Subsequently, an MTT assay was performed to define the suitable concentrations of drugs. Finally, real‑time PCR was performed 
to evaluate the mRNA expression levels of BDNF and GDNF in these stem cells. The results of the MTT assay showed that the 
treatment of EPI‑NCSCs with 1  mM VPA and 1.5  mM crocin, and the co‑treatment with 1  mM VPA and 500 µM crocin, led to 
the survival and proliferation of these stem cells. Moreover, the real‑time PCR results revealed that both VPA and crocin, both 
individually and in combination, can significantly increase the expression levels of BDNF and GDNF in EPI‑NCSCs. According to 
the findings of this study, both VPA and crocin, alone and in combination, are potential candidates for enhancing the capacity of 
EPI‑NCSCs to differentiate into neural lineages. Therefore, the co‑treatment of EPI‑NCSCs with these drugs can be employed for 
the treatment of various neurological disorders, such as spinal cord injury.
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INTRODUCTION
Brain‑derived neurotrophic factor (BDNF) and gli‑
al‑cell‑derived neurotrophic factor (GDNF) are both 
related to the neurotrophic factor family, which play 
essential roles in neural development, cell survival, 
differentiation, and axonal growth, in both the cen‑
tral and peripheral nervous systems, during develop‑
ment and in mature systems (Marsh and Blurton‑Jones, 
2017). During neurodegenerative disorders, such as spi‑
nal cord injury (SCI), Alzheimer’s disease, and Hunting‑
ton’s disease, neurotrophins can protect, preserve, and 
rehabilitate neuronal populations (Allen et al., 2013). 
Until now, various therapies have been considered for 
the treatment of neurodegenerative disorders, such as 
cell therapy, molecular therapy, and pharmaceutical 
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therapy, but none have been accurate. Hence, research‑
ers began to assess combination therapies for a range 
of neurological disorders (Neirinckx et al., 2013; Silva 
et al., 2014).
BDNF is a striking neurotrophin that is broadly ex‑
pressed in the central nervous system (CNS) (Chen et 
al., 2013). It was found that BDNF has the capacity to 
treat neurological disorders (Nagahara and Tuszynski, 
2011). When BDNF binds to its receptors, it activates 
a signaling pathway that leads to neural regeneration 
and the prevention of inflammatory responses and 
neuronal apoptosis (Chen et al., 2013). It is notable that 
BDNF is a vital signaling factor, due to its functions in 
neurogenesis, neuroprotection, axonal growth, myelin‑
ation, and synaptic plasticity during various CNS disor‑
ders (Harvey et al., 2015). Drugs that can upregulate the 
expression of BDNF and its downstream effectors, such 
as the phosphoinositide 3‑kinase (PI3K) pathway, the 
mitogen‑activated protein kinase (MAPK) pathway, and 
the cAMP response element‑binding protein (CREB), 
are suitable options for the treatment of neurodegen‑
erative disorders (Yoshii and Constantine‑Paton, 2010; 
Lin et al., 2016).
GDNF is another neurotrophic factor that is released 
from glial cells and has several effects that have at‑
tracted the attention of researchers for the treatment 
of neurodegenerative disorders. This neurotrophin ac‑
tivates caspase‑3/Akt, which subsequently leads to re‑
ductions in astrocyte cell death, the attenuation of mi‑
croglial activation, and the activation of the PI3K and 
the extracellular signal‑regulated kinase (ERK)‑MAPK 
pathways (Walker and Xu, 2018).
Recent trends in neurotrophic factor research have 
led to a proliferation of studies that show the benefits 
of neurotrophic factor overexpression in the human 
and rodent CNS as a potential therapeutic strategy 
(Tang et al., 2010; Marsh and Blurton‑Jones, 2017).
Cell therapy is one of the appropriate strategies 
for the treatment of neurodegenerative disorders. Di‑
verse sources and types of stem cells have been studied 
for use in stem cell therapy to treat neurodegenera‑
tive disorders, including neural stem cells, embryon‑
ic stem cells, Schwann cells, mesenchymal stem cells, 
and induced pluripotent stem cells (Martínez‑Morales 
et al., 2013; Silva et al., 2014). Epidermal neural crest 
stem cells (EPI‑NCSCs) have been widely employed for 
the treatment of various neurological disorders, such 
as spinal cord injury (SCI). These cells are multipotent 
stem cells with a high level of plasticity. Although these 
cells originate from the ectodermic layer (Sieber‑Blum 
and Hu, 2008), they can differentiate into both endo‑
dermal and ectodermal cells, such as neurons, Schwann 
cells, glia, sensory neurons, endocrine cells, smooth 
muscle cells, and pigment cells, and tissues, including 
bone, cartilage, and the connective tissue on the face 
and ventral neck (Sieber‑Blum et al., 2004). EPI‑NCSCs 
can be obtained through a minimally invasive proce‑
dure and can be expanded into a pure population of 
cells through cell culture techniques. Although these 
stem cells present strong migration abilities, they are 
not tumorigenic and can be used as autografts (Sie‑
ber‑Blum and Hu, 2008).
Valproic acid (VPA) is a well‑known drug used to 
treat a wide range of mental and neurological disor‑
ders, such as epilepsy, bipolar disorder, depression, 
schizophrenia, and migraine (Chateauvieux et al., 
2010). VPA, a short‑chain fatty acid, has attracted con‑
siderable interest, due to its neurogenic and neuro‑
protective effects during SCI treatment, through the 
inhibition of histone deacetylase (HDAC) and glycogen 
synthase kinase‑3 (GSK‑3). Many studies have empha‑
sized the potential role of VPA as an HDAC inhibitor 
that can upregulate several neurotrophic factors (Jung 
et al., 2008; Lv et al., 2012; Almutawaa et al., 2014). Be‑
cause VPA can also inhibit GSK‑3, VPA can enhance 
neuroprotective effects either directly or indirectly, 
through the Wnt/β‑catenin, PI3K/Akt, and MAPK/ERK 
(MEK) pathway, during psychiatric and neurodegen‑
erative disorder, such as bipolar disorder and Alzhei‑
mer’s disease. In addition, VPA can trigger a cascade of 
events that neutralize and compensate for the events 
associated with secondary damage during SCI, through 
neuroprotective effects and neurogenesis, via HDAC 
and GSK‑3 inhibition (Chu et al., 2015; Li et al., 2017). 
During a neural condition, such as SCI, cell damage 
occurs due to microglial activation, the production of 
various inflammatory cytokines, and the activation of 
the nuclear factor (NF)‑kB signaling pathway, which 
produces NF‑kB proteins that bind to gene promot‑
ers in response to neuroinflammation. This signaling 
pathway is an important pathway associated with sec‑
ondary damage during SCI. Hence, VPA, due to HDAC 
inhibition, can maintain NF‑kB in its acetylated state 
(inactive), which can subsequently suppress the acti‑
vation of microglia and consequent inflammatory re‑
sponses (Chen et al., 2018). 
Crocin is a primary component in saffron (Crocus sa-
tivus L.) extract. Crocin is thought to be a useful candi‑
date for the treatment of neurodegenerative disorders 
because of its anti‑inflammatory, anti‑apoptotic, and 
antioxidant effects, which can reduce neuroinflamma‑
tion and cell death during neurodegenerative disorders 
(Wang et al., 2015; Yorgun et al., 2017). 
This study was designed to evaluate the effects of two 
neuroprotective agents, VPA and crocin, on the mRNA 
expression levels of BDNF and GDNF in EPI‑NCSCs.
Our study provided the first evidence for the po‑
tential use of VPA and crocin as a co‑treatment in 
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EPI‑NCSCs to regulate the mRNA expression levels of 
two neurotrophic factors, BDNF and GDNF.
Overall, based on the wide range of studies that have 
assessed the impacts of various drugs on EPI‑NCSCs 
(Salehi et al., 2019), in the current investigation, we 
evaluated the synergistic effects of VPA and crocin on 
BDNF and GDNF expression levels in EPI‑NCSCs, in an 
in vitro context. This therapeutic approach may subse‑
quently ameliorate conditions associated with neurode‑
generative disorders and may ultimately be employed 
in in vivo models of neurodegenerative disorders.
MATERIALS 
Epidermal neural crest stem cell isolation 
and culture
In this study, Wistar rats (3‑4 weeks old) were sac‑
rificed by cervical dislocation and the whisker pad 
follicles were dissected and the bulges were rolled out 
from the hair follicle capsules, as described previously 
(Sieber‑Blum et al., 2004; Pandamooz et al., 2013, 2016). 
EPI‑NCSCs, 3‑4 days after bulge explantation, were mi‑
grated from the bulge region of the hair follicles into 
collagen‑coated plates (Fig. 1). The culture medium con‑
sisted of 85% α‑minimum essential medium (α‑MEM, Bi‑
oidea, Iran), 10% fetal bovine serum (FBS, Bioidea, Iran), 
5% day‑11 chick embryo extract (CEE, purchased from 
Shahid Beheshti University), and penicillin/streptomy‑
cin (100 U/ml, Bio‑idea, Iran). The migrated EPI‑NCSCs 
were incubated at 37°C, in the humidified atmosphere 
of a 5% CO2 incubator (Hu et al., 2006).
Cell viability test
To determine the non‑toxic doses of VPA (Darou Pa‑
khsh Pharma. Chem. Co, Iran) and crocin (Puyesh Darou 
Sina, Iran), an MTT assay was performed. EPI‑NCSCs 
were seeded in 96‑well plates, at a density of 5×103 
cells/well, 24 h prior to treatment. Then, EPI‑NCSCs 
were treated with various concentrations of VPA (0.1, 
0.5, 1, 2, 5, 7, and 10 mM), crocin (12.5, 50, 100, 500, 
1,000, 1,500, 2,000, and 2,500 µM) or both of VPA (1 mM) 
and crocin (12.5, 50, 100, 200, 500, 1,000, 1,500, 2,000, 
and 2,500 µM), for 72 h. Each treatment was repeated at 
least three times. After 72 h of treatment, an MTT solu‑
tion (125 µg/ml, Sigma, USA) was added to the treated 
cells, for 3 h, at 37°C. The medium was then aspirated, 
the formazan product was dissolved in dimethylsulfox‑
ide (DMSO, Merck, Germany), and the absorbance was 
read at 570 nm, using an iMark™ Microplate Absorbance 
Reader (Bio‑Rad, USA).
RNA extraction, cDNA synthesis, 
and Real‑time PCR
In this study, the effects of VPA and crocin, both 
alone and in combination, on the transcription lev‑
els of GDNF and BDNF in EPI‑NCSCs were evaluated 
by real‑time PCR. EPI‑NCSCs were seeded at a density 
of 20,000 cells/well in four 6‑well plates. On the first 
day, the cells were treated with VPA (1 mM), crocin 
(1.5 mM), or both VPA (1 mM) and crocin (500 µM), 
while a control group received drug‑free medium. 
On the third and fifth days of the experiment, the 
entire medium in each well was renewed with fresh 
medium containing the appropriate drugs. On the 
seventh day, total RNA was extracted from both con‑
trol and treated groups, using a total RNA extraction 
kit (Parstous Biotechnology, Iran), according to the 
manufacturer’s instructions. Then, the RNA concen‑
trations were determined using a Nanodrop system 
(Thermo Scientific, USA), and afterward, cDNA was 
synthesized from the extracted mRNA for each sam‑
ple, using an easy cDNA synthesis kit (Parstous Bio‑
technology, Iran), with the aid of oligo dT primers. 
Finally, to compare the expression levels of target 
genes between the treated groups and the control 
Fig.  1. Timeline scheme. First, EPI‑NCSCs were seeded in 96‑ and 6‑well 
plates. On the first day, cells were treated with VPA, crocin, or both VPA 
and crocin, and a  control group received a  drug‑free medium. On the 
third and fifth days, the entire medium in each well was renewed with the 
appropriate drug‑containing medium. On the seventh day, total RNA was 
extracted from both control and treatment groups, cDNA was synthesized 
using the mRNA extracted from each sample, and real‑time PCR was 
performed.
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group, real‑time PCR was performed using a SYBER 
Green PCR master mix (Takara, Japan), in a Corbett 
research rotor‑gene RG6000 Real‑Time rotary ana‑
lyzer PCR machine (Corbett, Australia) (Fig. 2). Final‑
ly, the results were normalized against the expres‑
sion level of a housekeeping gene, beta‑actin (β‑ac‑
tin). The specific forward (F) and reverse (R) primer 
(5ʹ→3ʹ) sequences used for real‑time PCR are listed in 
Table I. Data were analyzed using the ΔΔCt method 
(Livak and Schmittgen, 2001).
Statistical analysis
Results are expressed as the mean ± standard error 
of the mean (SEM). Statistical analysis was performed 
using either an independent Student’s t‑test indepen‑
dent or a one‑way analysis of variance (ANOVA), fol‑
lowed by post hoc comparisons. The Student’s t‑test 
was employed to compare the differences between 
two groups and the one‑way ANOVA was employed to 
compare more than two groups. Differences between 
Table. I. List of primers.
Gene Forward primer (5ʹ→3ʹ) Reverse primer (5ʹ→3ʹ) Amplicon length (bp)
BDNF CGATTAGGTGGCTTCATAGGAGAC CAGAACAGAACAGAACAGAACAGG 182
GDNF GCTGACCAGTGACTCCAATATGC CCTCTGCGACCTTTCCCTCTG 192
β‑actin TCTATCCTGGCCTCACTGTC AACGCAGCTCAGTAACAGTCC 122
Fig. 2. Migration of epidermal neural crest stem cells from the bulge area. A) Two to three days post explantation of the hair follicle bulge area, EPI‑NCSCs 
migrate from the bulge niche. B) The expansion of these stem cells occurs under in vitro conditions, and following 7 days in culture, these migrated stem 
cells form a pure colony of stem cells (scale bar: 1000 µm).
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groups were considered significant at p<0.05 (*), p<0.01 
(**), and p<0.001 (***).SPSS software 22.0 was used for 
statistical analyses.
RESULTS 
In vitro expansion of EPI‑NCSCs
The isolation of EPI‑NCSCs and their in vitro expan‑
sion were performed according to procedures previ‑
ously described by our research group (Hu et al., 2006; 
Pandamooz et al., 2016, 2017). EPI‑NCSCs migrated 
2–3 days after explantation from whisker bulges, pre‑
senting with stellate morphology (Fig. 2A and 2B). The 
proliferation of EPI‑NCSCs, in culture medium contain‑
ing α‑MEM, 10% FBS, and 5% CEE, was examined daily 
prior to sub‑culturing using an inverted microscope 
(Pandamooz et al., 2016).
Cell viability
In the current investigation, the MTT assay was per‑
formed to define the concentrations of VPA and crocin 
that did not cause significant decreases in cell survival 
and did not enhance cell proliferation compared with 
the non‑treated control group. EPI‑NCSCs were treated 
with various concentrations of VPA and crocin for 72 h. 
The obtained data revealed that none of the tested VPA 
concentrations (0.1, 0.5, and 1 mM) caused significant 
cell death, and cell viability was similar to that for the 
control group. According to the results of the MTT as‑
say, concentrations of 2, 5, and 7 mM VPA decreased cell 
survival by approximately 40% (p<0.05), and the 10 mM 
concentration decreased survival by approximately 60% 
(p<0.001) and demonstrated significant cytotoxic effects 
in EPI‑NCSCs. According to the aim of this study, the 
proper VPA dose for the treatment of EPI‑NCSCs was de‑
termined to be 1 mM, a concentration at which cell via‑
bility impacts were similar to those observed for the con‑
trol group, with no significant effects on cell death or cell 
proliferation; therefore this dose was selected to define 
the effects of VPA on the mRNA expression levels of the 
selected trophic factors. In addition, the assessment of 
crocin showed that concentrations of 12.5, 50, 100, 500, 
and 1,000 µM promoted cell proliferation by approx‑
imately 125%, 123%, 122%, 117%, and 109%, respective‑
ly, compared with the control group. In contrast, 2,000 
and 2,500 µM crocin had cytotoxic effects in EPI‑NCSCs 
(p<0.001). Moreover, the 1,500 µM concentration of crocin 
was determined to be the appropriate dose for the treat‑
ment of EPI‑NCSCs because it was the most effective dose 
and had no cytotoxic effects. The results of combination 
Fig. 3. Investigating the effects of various concentrations of VPA and crocin, 
both alone and in combination, on the cell viability and proliferation of 
EPI‑NCSCs. A) EPI‑NCSCs were treated with different concentrations of VPA, 
ranging from 0.1 to 10 mM. B) The effects of different concentrations of 
crocin on these stem cells were defined using the MTT assay. C) Moreover, 
these stem cells were treated with a combination of VPA and crocin, using 
a  VPA concentration of 1  mM and crocin concentrations ranging from 
12.5 to 2,500 μM. Co‑treatment with VPA (1 mM) and crocin, at different 
concentrations, showed that VPA (1  mM) combined with 500 µM crocin 
was an appropriate dose, which does not cause cell death or proliferation. 
Values are mean ± SEM (n=3), p<0.001***, p<0.01**, p<0.05*.
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treatments, using VPA (1 mM) and different doses of cro‑
cin, showed that 1,000, 1,500, 2,000, and 2,500 µM crocin 
decreased cell survival significantly (p<0.001) compared 
with the control group. As a result, 500 µM was chosen 
as the appropriate dose for use during co‑treatment be‑
cause this dose resulted in approximately 90% cell viabil‑
ity, which was appropriate for our scope (Fig. 3).
Effects of VPA on BDNF and GDNF mRNA 
expression levels in EPI‑NCSCs 
Following the treatment of EPI‑NCSCs with a 1 mM 
concentration of VPA for 7 days, a significant increase in 
the BDNF mRNA expression level (p<0.001) was observed 
compared with the control sample. The treatment of 
EPI‑NCSCs for 7 days with VPA (1 mM) also increased 
the GDNF mRNA expression level, but this increase was 
not significant compared with the control group (Fig. 4). 
Our study showed that renewing the whole medium on 
the third and fifth days enhanced the effects of VPA on 
BDNF mRNA expression levels compared with the results 
observed in a study where the medium was not renewed 
(Pandamooz et al., 2017).
Effect of crocin on BDNF and GDNF mRNA 
expression in EPI‑NCSCs 
The gene expression analysis of the BDNF mRNA ex‑
pression level showed a significant increase (p<0.001) 
in EPI‑NCSCs following treatment with 1,500 µM cro‑
cin compared with that in the control group, but no 
significant increase was observed for the GDNF mRNA 
expression level (p>0.05) (Fig. 5).
Synergistic effects of VPA and crocin on 
neurotrophic factor mRNA expression levels 
in EPI‑NCSCs
In this study, the combination treatment of VPA 
(1 mM) and crocin (500 µM) for 7 days was examined. 
In EPI‑NCSCs co‑treated with VPA and crocin, the mRNA 
expression levels of BDNF and GDNF significantly in‑
creased, as quantified by real‑time PCR, compared with 
those following treatment using either VPA or crocin 
alone (p<0.001). In addition, the GDNF mRNA expression 
level increased after co‑treatment with VPA and crocin 
(p<0.05), whereas treatments using either VPA and cro‑
cin alone had no significant effects on GDNF mRNA ex‑
pression levels (Fig. 6A, B).
DISCUSSION
In this study, we investigated, for the first time, the 
effects of crocin, alone and in combination with VPA, 
on EPI‑NCSCs by evaluating the mRNA expression levels 
of BDNF and GDNF. We also showed that co‑treatment 
with VPA and crocin additively enhanced the mRNA ex‑
pression levels of BDNF and GDNF.
Researchers found that both neurotrophic factors, 
BDNF and GDNF, are important for the survival, main‑
Fig.  4. mRNA expression levels of BDNF and GDNF in EPI‑NCSCs 
treated with VPA for 7 days, during which the medium was renewed 
twice. Here, the impact of treatment with 1  mM VPA on the mRNA 
expression level of BDNF in EPI‑NCSCs was defined by real‑time PCR. 
The influence of this drug was also assessed for the expression level 
of GDNF mRNA. Values are mean ± SEM (n=3), p<0.001***, p<0.01**, 
p<0.05*.
Fig. 5. mRNA expression levels of BDNF and GDNF in EPI‑NCSCs after 
treatment with crocin for 7  days, during which the medium was 
renewed twice. Crocin can significantly increase the expression level 
of BDNF mRNA in EPI‑NCSCs compared with the control group. The 
expression level of GDNF did not elevate significantly following this 
treatment compared with that in the control group. Values are mean 
± SEM (n=3), p<0.001***, p<0.01**, p<0.05*.
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tenance, and restoration of neurons in the CNS. The 
lack of these factors has been associated with several 
neuropathological conditions, and treatment modal‑
ities using these factors represent robust therapeutic 
options for neurodegenerative disorders (Allen et al., 
2013). Here, we evaluated the mRNA expression lev‑
els of BDNF and GDNF in EPI‑NCSCs following 7 days 
of treatment with VPA, crocin, or the co‑treatment of 
VPA and crocin, under conditions in which the whole 
medium was renewed on the third and fifth days. Neu‑
rotrophic factors, such as BDNF and GDNF, activate the 
Ras‑Raf‑MEK‑ERK signaling pathway, which causes neu‑
ronal growth, regeneration, and neurogenesis (Allen et 
al., 2013). After neurotrophins bind to their receptors, 
they regulate and activate MAPK, PI3K, and phospho‑
lipase Cγ (PLC γ) (Chen et al., 2013). GDNF enhances 
neuronal survival in the CNS and peripheral nervous 
system and influences a large population of cells, in‑
cluding sensory and motor ganglia and Purkinje cells 
in the cerebellum. BDNF also plays a role in the mainte‑
nance of sensory and motor neurons in the spinal cord 
(Allen et al., 2013).
Neural restoration and the replacement of lost cells 
are two important goals in the treatment of neurode‑
generative disorders. Other aims during the treatment 
of neurodegenerative disorders include the enhance‑
ment of axonal repair, increased growth factor expres‑
sion, the neutralization of inhibitory factors, reduc‑
tions in glial scar formation, and improved regener‑
ation (Bunge 2008). Numerous studies have reported 
that EPI‑NCSCs are capable of differentiating into both 
neuronal and glial cells (Sieber‑Blum 2006; 2010; Sie‑
ber‑Blum and Grim 2004). In 2010, Sieber‑Blum claimed 
that EPI‑NCSC transplantation into an animal model of 
SCI resulted in a series of effects, including the replace‑
ment of glial and neuronal cells, trophic factor support, 
the induction of angiogenesis, the formation and reg‑
ulation of glial scars, and the reinforcement of repair 
mechanisms, which improved the recovery of SCI mice 
(Sieber‑Blum 2010).
In contrast, VPA is currently being used in clinical 
trials to treat seizures, depression, and epilepsy (Cha‑
teauvieux et al., 2010). VPA exerts effects on several cell 
signaling pathways, via its HDAC inhibitory functions. 
HDAC inhibition causes the hyperacetylation of core 
histones, which leads to gene activation or the sup‑
pression and regulation of gene expression. Therefore, 
VPA, via HDAC inhibition, can increase the acetylation 
of histones, leading to the gene expression of neuro‑
trophic factors (Wu et al., 2008), which play important 
roles in neuroprotection and neurogenesis, by protect‑
ing surviving neurons from death and stimulating the 
growth of neural cells (Chu et al., 2015). In an animal 
model of SCI and under conditions of cellular excito‑
Fig. 6. mRNA expression levels of BDNF and GDNF in EPI‑NCSCs treated 
with a  combination of crocin and VPA for 7  days, during which the 
medium was renewed twice. (A) The significant upregulation of BDNF 
mRNA expression levels in EPI‑NCSCs. The expression level of GDNF 
also elevates significantly following this treatment compared with that 
in the control group. Comparison of mRNA expression levels for BDNF 
(B) and GDNF (C) after treatment with VPA and crocin, alone and in 
combination, in EPI‑NCSCs for 7  days, during which the medium was 
renewed twice. Values are mean ± SEM (n=3), p<0.001***, p<0.01**, 
p<0.05*.
Valproic acid & crocin effects on BDNF and GDNF in EPI‑NSCs 45Acta Neurobiol Exp 2020, 80: 38–46
toxicity, VPA functions via HDAC inhibition, which in‑
creases cell viability, enhances BDNF expression, pre‑
vents the activation of NF‑kB, and inhibits ER stress 
(Scheuing et al., 2014). However, there are some studies 
describing an actual decrease in the gene expression 
levels of BDNF in the brain after VPA administration 
(Umka et al., 2010; Buzgoova et al., 2019). It has been 
well‑documented that VPA performs an important role 
in the treatment of CNS damage, via the induction of 
neuronal differentiation and the enhancement of neu‑
ral growth (Kim et al., 2005). Here, we detected a sig‑
nificant increase in the BDNF mRNA expression levels 
in EPI‑NCSCs following treatment with 1 mM VPA for 
7 days, although no significant alteration was detect‑
ed in the GDNF mRNA expression level. Although our 
recent investigation showed increased BDNF and GDNF 
mRNA expression levels in EPI‑NCSCs following VPA 
treatment (Pandamooz et al., 2019), here, we revealed 
that the expression of both BDNF and GDNF mRNA were 
upregulated more strongly if the medium was renewed 
on the third and fifth days.
Additionally, numerous studies have examined the 
antioxidant, anti‑inflammatory, anti‑tumor, cytotox‑
icity, and neuroprotective effects of crocin (Vahdati 
Hassani et al., 2014; Wang et al., 2015; Samini and Sa‑
marghndian 2016). In recent years, there has been an 
increasing amount of literature describing the effects 
of crocin on neurodegenerative disorders, such as Alz‑
heimer’s disease, depression, anxiety, and schizophre‑
nia. Crocin inhibits apoptosis through the PI3K/AKT 
signaling pathway and increases the Bcl‑2/BAX ratio 
(Khazdair et al., 2015). Our result showed that crocin 
treatment can significantly increase the BDNF mRNA 
expression level. However, only a slight increase has 
been observed in the mRNA expression level of GDNF 
after crocin treatment compared with that of the con‑
trol group, which was not statistically significant. 
A previous study reported that crocin increased CREB, 
BDNF, and VGF protein expression in the rat hippocam‑
pus (Razavi et al., 2017).
The most interesting finding was that the co‑treat‑
ment of VPA and crocin significantly increased both 
BDNF and GDNF mRNA expression levels compared 
with treatment using VPA or crocin alone. These find‑
ings further support the concept of a novel combina‑
tion therapy for EPI‑NCSCs, using an HDAC inhibitor 
(such as VPA) and the natural product crocin, in in 
vivo neurodegenerative disorder models, to upregulate 
BDNF and GDNF, which are both essential for neural de‑
velopment and regeneration. We found that both VPA 
and crocin treatment significantly increased the levels 
of BDNF mRNA expression and that, moreover, VPA and 
crocin co‑treatment caused an additive increase in the 
BDNF mRNA expression level.
Together, these results provide important insights 
into the co‑treatment of VPA and crocin, which can up‑
regulate BDNF and GDNF mRNA expression levels, re‑
vealing their synergistic effects.
Further research should be performed to investi‑
gate the co‑treatment of EPI‑NCSCs using VPA and cro‑
cin in in vivo models, by measuring neurotrophin pro‑
tein levels, which may further support the invaluable 
combination of these strategies for the treatment of 
neurodegenerative disorders.
CONCLUSION 
The present study was designed to determine the 
effects of VPA and crocin on the EPI‑NCSC survival rate 
and proliferation and the expression of neurotrophic 
factors. One of the most significant findings that has 
emerged from this study is that the combination of VPA 
and crocin and the renewal of the culture medium ev‑
ery other day can affect the BDNF and GDNF mRNA ex‑
pression levels in EPI‑NCSCs.
REFERENCES
Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK (2013) GDNF, NGF 
and BDNF as therapeutic options for neurodegeneration. Pharmacol 
Therapeut 138: 155–175.
Almutawaa W, Kang NH, Pan Y, Niles LP (2014) Induction of neurotrophic 
and differentiation factors in neural stem cells by valproic acid. Basic 
Clin Pharmacol 115: 216–221.
Bunge MB (2008) Novel combination strategies to repair the injured mam-
malian spinal cord. J Spinal Cord Med 31: 262–269.
Buzgoova K, Graban J, Balagova L, Hlavacova N, Jezova D (2019) Brain derived 
neurotrophic factor expression and DNA methylation in response to sub-
chronic valproic acid and/or aldosterone treatment. Croat Med J 60: 71.
Chateauvieux S, Morceau F, Dicato M, Diederich M (2010) Molecular and ther-
apeutic potential and toxicity of valproic acid. Biomed Res Int 2010: 1–18.
Chen AI, Xiong LJ, Tong Y U, Mao M (2013) The neuroprotective roles of 
BDNF in hypoxic ischemic brain injury. Biomed Rep 1: 167–176.
Chen S, Ye J, Chen X, Shi J, Wu W, Lin W, Li S (2018) Valproic acid attenuates 
traumatic spinal cord injury‑induced inflammation via STAT1 and NF‑κB 
pathway dependent of HDAC3. J Neuroinflamm 15: 150.
Chu T, Zhou H, Lu L, Kong X, Wang T, Pan B, Feng S (2015) Valproic acid‑me-
diated neuroprotection and neurogenesis after spinal cord injury: from 
mechanism to clinical potential. Regen Med 10: 193–209.
Harvey AR, Lovett SJ, Majda BT, Yoon JH, Wheeler LP, Hodgetts SI (2015) 
Neurotrophic factors for spinal cord repair: which, where, how and 
when to apply, and for what period of time? Brain Res 1619: 36–71.
Hu YF, Zhang ZJ, Sieber‑Blum M (2006) An epidermal neural crest stem cell 
(EPI‑NCSC) molecular signature. Stem Cells 24: 2692–2702.
Jung GA, Yoon JY, Moon BS, Yang DH, Kim HY, Lee SH, Choi KY (2008) Val-
proic acid induces differentiation and inhibition of proliferation in neu-
ral progenitor cells via the beta‑catenin‑Ras‑ERK‑p21 Cip/WAF1 path-
way. BMC Cell Biol 9: 66.
Khazdair MR, Boskabady MH, Hosseini M, Rezaee R, Tsatsakis AM (2015) 
The effects of Crocus sativus (saffron) and its constituents on nervous 
system: A review. Avicenna J Phytomed 5: 376.
46 Baharvand et al. Acta Neurobiol Exp 2020, 80: 38–46
Kim AJ, Shi Y, Austin RC, Werstuck GH (2005) Valproate protects cells from 
ER stress‑induced lipid accumulation and apoptosis by inhibiting glyco-
gen synthase kinase‑3. J Cell Sci 118: 89–99.
Li Z, Wu F, Zhang X, Chai Y, Chen D, Yang Y, Wang Z (2017) Valproate atten-
uates endoplasmic reticulum stress‑induced apoptosis in SH‑SY5Y cells 
via the AKT/GSK3β signaling pathway. Int J Mol Sci 18: 315.
Lin G, Zhang H, Sun F, Lu Z, Reed‑Maldonado A, Lee YC, Lue TF (2016) 
Brain‑derived neurotrophic factor promotes nerve regeneration by acti-
vating the JAK/STAT pathway in Schwann cells. Transl Androl Urol 5: 167.
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data 
using real‑time quantitative PCR and the 2−ΔΔCT method. Methods 25: 
402–408.
Lv L, Han X, Sun Y, Wang X, Dong Q (2012) Valproic acid improves locomo-
tion in vivo after SCI and axonal growth of neurons in vitro. Exp Neurol 
233: 783–790.
Marsh S E, Blurton‑Jones M (2017) Neural stem cell therapy for neurode-
generative disorders: the role of neurotrophic support. Neurochem Int 
106: 94–100.
Martínez‑Morales PL, Revilla A, Ocana I, Gonzalez C, Sainz P, McGuire D, 
Liste I (2013) Progress in stem cell therapy for major human neurologi-
cal disorders. Stem Cell Rev Rep 9: 685–699.
Nagahara A H, Tuszynski M H (2011) Potential therapeutic uses of BDNF 
in neurological and psychiatric disorders. Nat Rev Drug Discov 10: 209.
Neirinckx V, Coste C, Rogister B, Wislet‑Gendebien S (2013) Concise review: 
adult mesenchymal stem cells, adult neural crest stem cells, and therapy of 
neurological pathologies: a state of play. Stem Cells Transl Med 2: 284–296.
Pandamooz S, Saied MS, Nabiuni M, Dargahi L, Pourghasem M (2016) Eval-
uation of epidermal neural crest stem cells in organotypic spinal cord 
slice culture platform. Folia Biol 62: 263.
Pandamooz S, Naji M, Alinezhad F, Zarghami A, Pourghasem M (2013) The 
influence of cerebrospinal fluid on epidermal neural crest stem cells 
may pave the path for cell‑based therapy. Stem Cell Res Ther 4: 84.
Pandamooz S, Salehi  MS, Safari A, Azarpira N, Heravi  M, Ahmadiani A, 
Dargahi L (2019) Enhancing the expression of neurotrophic factors in 
epidermal neural crest stem cells by valproic acid: A potential candidate 
for combinatorial treatment. Neurosci Lett 704: 8–14.
Razavi BM, Sadeghi M, Abnous K, Hasani FV, Hosseinzadeh H (2017) Study of 
the role of CREB, BDNF, and VGF neuropeptide in long term antidepres-
sant activity of crocin in the rat cerebellum. Iran J Pharm Res 16: 1452.
Salehi  MS, Borhani‑Haghighi A, Pandamooz S, Safari A, Dargahi  L, 
Dianatpour  M, Tanideh N (2019) Dimethyl fumarate up‑regulates ex-
pression of major neurotrophic factors in the epidermal neural crest 
stem cells. Tissue Cell 56: 114–120.
Samini F, Samarghandian S (2016) Neuroprotective effects of Crocus Sati-
vus L. and its main constituents. Der Pharma Lett 8: 25–9.
Scheuing L, Chiu C T, Liao H M, Linares G R, Chuang D M (2014) Preclinical 
and clinical investigations of mood stabilizers for Huntington’s disease: 
what have we learned? Int J Biol Sci 10: 1024.
Sieber‑Blum M, Grim M, Hu YF, Szeder V (2004) Pluripotent neural crest 
stem cells in the adult hair follicle. Dev Dynam 231: 258–269.
Sieber‑Blum M (2010) Epidermal neural crest stem cells and their use in 
mouse models of spinal cord injury. Brain Res Bull 83: 189–193.
Sieber‑Blum M, Grim M (2004) The adult hair follicle: cradle for pluripotent 
neural crest stem cells. Birth Defects Res C 72: 162–172.
Sieber‑Blum M, Hu Y (2008) Epidermal neural crest stem cells (EPI‑NCSC) 
and pluripotency. Stem Cell Rev 4: 256–260.
Sieber‑Blum M, Schnell L, Grim M, Hu YF, Schneider R, Schwab ME (2006) 
Characterization of epidermal neural crest stem cell (EPI‑NCSC) grafts in 
the lesioned spinal cord. Mol Cell Neurosci 32: 67–81.
Silva NA, Sousa N, Reis RL, Salgado AJ (2014) From basics to clinical: a com-
prehensive review on spinal cord injury. Prog Neurobiol 114: 25–57.
Tang S, Machaalani R, Waters KA (2010) Immunolocalization of pro‑and 
mature‑brain derived neurotrophic factor (BDNF) and receptor TrkB in 
the human brainstem and hippocampus. Brain Res 1354: 1–14.
Umka J, Mustafa S, El Beltagy M, Thorpe A, Latif L, Bennett G, Wigmore PM 
(2010) Valproic acid reduces spatial working memory and cell prolifera-
tion in the hippocampus. Neuroscience 166: 15–22.
Vahdati Hassani F, Naseri V, Razavi BM, Mehri S, Abnous K, Hosseinzadeh 
H (2014) Antidepressant effects of crocin and its effects on transcript 
and protein levels of CREB, BDNF, and VGF in rat hippocampus. DARU 
22: 16.
Walker M, Xu XM (2018) History of glial cell line‑derived neurotrophic factor 
(GDNF) and its use for spinal cord injury repair. Brain Sci 8: 109.
Wang K, Zhang L, Rao W, Su N, Hui H, Wang L, Fei Z (2015) Neuroprotective 
effects of crocin against traumatic brain injury in mice: Involvement of 
notch signaling pathway. Neurosci Lett 591: 53–58.
Wu X, Chen PS, Dallas S, Wilson B, Block ML, Wang CC, Chuang DM (2008) 
Histone deacetylase inhibitors up‑regulate astrocyte GDNF and BDNF 
gene transcription and protect dopaminergic neurons. Int J Neuropsy-
choph 11: 1123–1134.
Yorgun M A, Rashid K, Aslanidis A, Bresgen C, Dannhausen K, Langmann T 
(2017) Crocin, a plant‑derived carotenoid, modulates microglial reactivi-
ty. Biochem Biophys Rep 12: 245–250.
Yoshii A, Constantine‑Paton  M (2010) Postsynaptic BDNF‑TrkB signal-
ing in synapse maturation, plasticity, and disease. Dev Neurobiol 70: 
304–322. 
